Merck and Moderna Report Positive Phase 3 Results for Personalized Melanoma Therapy Merck and Moderna have announced positive topline results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene in combination with pembrolizumab as adjuvant treatment for patients with completely resected stage IIB to IV melanoma. The investigational regimen met the study’s primary endpoint of recurrence-free survival and a key secondary endpoint measuring the time patients rema

AstraZeneca and Daiichi Sankyo reported that Enhertu (trastuzumab deruxtecan) met its primary endpoint in the DESTINY-Lung04 study, showing a clear and meaningful extension of progression-free survival versus current first-line therapy in patients with HER2-mutant advanced non-squamous non-small cell lung cancer. In parallel, HUTCHMED announced that the SAFFRON trial met both its progression-free and overall survival endpoints for Tagrisso (osimertinib) plus Orpathys (savolit

BEST SELLING CANCER DRUGS | TOP ONCOLOGY DRUGS | 2025 BEST SELLING CANCER DRUGS 2025 Rank Brand Company Indications Revenues $ billion 1 Keytruda Merck Melanoma, NSCLC, HNSCC, Hodgkin Lymphoma, Urothelial Cancer, RCC, HCC and several other cancers $31.7 2 Darzalex Johnson and Johnson Multiple myeloma $14.5 3 Opdivo Bristol Myers Squibb Melanoma, NSCLC, Hodgkin Lymphoma, Urothelial Cancer, RCC, HCC and several other cancers $10.0 4 Tagrisso AstraZeneca EGFR positive NSCLC $7.2

Novartis’ Pluvicto Shows Deeper PSA Responses in Hormone-Sensitive Prostate Cancer Novartis has reported new findings from the PSMAddition trial showing that Pluvicto (lutetium-177 vipivotide tetraxetan), when added to standard therapy, significantly improves prostate-specific antigen (PSA) outcomes in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). The data indicate that combining Pluvicto with standard of care, comprising an androgen recept

NHS England will enhance bowel cancer screening sensitivity starting next month, potentially detecting 600 additional early-stage cases annually and preventing thousands more through polyp removal. NHS lowers FIT threshold to detect bowel cancers: Enhanced Screening Threshold From February 2026, NHS England reduces the faecal immunochemical test (FIT) positivity threshold from 120 µg Hb/g to 80 µg Hb/g, increasing colonoscopy referrals by 35% for patients over 50. This target

The European Medicines Agency (EMA) has accepted for review a Type II variation application for trastuzumab deruxtecan in combination with pertuzumab as an initial treatment option for adults with unresectable or metastatic HER2 positive breast cancer. The antibody drug conjugate, discovered by Daiichi Sankyo and co‑developed and co‑commercialized with AstraZeneca, is already authorized in later‑line HER2 positive settings, and this filing seeks to move the regimen into the f

FDA Greenlights Breyanzi: Pioneering CAR T-Cell Therapy for Marginal Zone Lymphoma The U.S. Food and Drug Administration has approved Breyanzi (lisocabtagene maraleucel) for adults battling relapsed or refractory marginal zone lymphoma (MZL) after at least two prior lines of systemic therapy. This groundbreaking decision positions Breyanzi as the first CAR T-cell therapy approved in the U.S. for this challenging rare B-cell malignancy, offering new hope to patients with limit

The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly's Jaypirca (pirtobrutinib), making it the first and only non-covalent, reversible Bruton tyrosine kinase (BTK) inhibitor approved to treat adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously received covalent BTK inhibitor therapy. The approval also converts the company's December 2023 accelerated approval into a tradi

Roche recently disclosed promising findings from the phase III lidERA Breast Cancer trial, where their experimental oral drug, giredestrant, showed a significant improvement in invasive disease-free survival compared to standard endocrine therapies. This study involved over 4,100 patients diagnosed with early-stage breast cancer characterized by oestrogen receptor-positive (ER+), HER2-negative tumors. The trial’s interim analysis revealed that giredestrant not only met but su

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved Epkinly (epcoritamab) administered subcutaneously in combination with rituximab and lenalidomide (EPKINLY + R2) for adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least one prior systemic therapy. This newly approved regimen is the first and only bispecific antibody combination therapy available for this patient population. The approval was granted base

Merck's Keytruda (pembrolizumab) Achieves Primary Goal of Event-Free Survival (EFS) in Perioperative Treatment for Patients with Resected...

Merck has announced the discontinuation of its Phase 3 KeyVibe-008 trial, which was investigating a fixed-dose combination of...

April 08, 2024 Krazati plus cetuximab showed improvement in objective response rate in patients with KRASG12C-mutated CRC Mirati...

January 09, 2024 FDA raised concerns regarding manufacturing facility of Astellas' zolbetuximab but had no comments on efficacy and...

November 01, 2023 Keytruda Demonstrated Improvement in Overall Survival in Patients with Renal Cell Carcinoma Merck has recently unveiled...

BeiGene, a prominent global biotechnology company, has recently shared positive regulatory updates regarding its innovative cancer...

The Phase 3 MARIPOSA-2 study has achieved significant breakthroughs in treating EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC),...

BMS announced that Breyanzi (lisocabtagene maraleucel) met the primary endpoint of the overall response rate in two types of...

Janssen and AbbVie announced they would withdraw mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL) applications in the US....

Novartis presented the positive results of the NATALEE study, demonstrating the benefit of Kisqali (ribociclib) plus endocrine therapy in...

Astellas and Pfizer announced positive topline results from the Phase 3 EMBARK trial, which evaluated the effectiveness of Xtandi...

Keytruda met the primary endpoint in the Phase 3 KEYNOTE-859 trial in patients with HER2-negative gastric cancer. Merck announced that...

FDA accepted the NDA of GSK's momelotinib for myelofibrosis GSK announced that the U.S. Food and Drug Administration accepted the new...

October 17, 2022 Bayer expands its breast cancer portfolio by expanding the OASIS program of elinzanetant. Bayer announced that it had...